Watched a video today where Cynata uses the FDA CRL to target MSB saying they are inferior on cost, efficacy, number of infusions and consistency of product.
I recall SI stating that induced pluripotent stem cells have issues with potential side effects and not being sufficiently differentiated to be as effective. Have I confused Cynata MSCs with others or is this accurate? Clearly Cynata is much earlier on and is years away from competing, as acknowledged by the CEO presenting, but I am interested to understand if induced pluripotent stem cells are equivalent or better to MSBs MSCs.
Cynata claiming their cells far superior to MSB's
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
-0.015(1.49%) |
Mkt cap ! $1.136B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.02 | 99.5¢ | $2.005M | 1.991M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 14424 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 63643 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |